• CHIR-99021 and the Logic of Neuronal Fate

  2026-08-21

  CHIR-99021, also known as CT99021, is examined here as a time-resolved GSK-3 perturbation tool rather than a generic differentiation reagent. By connecting Wnt pathway control with the post-transcriptional regulation of TRIM46, this guide shows how assay design can distinguish neuronal identity from neuronal maturation.

• Mithramycin A: From G-C DNA to Translation

  2026-08-20

  Mithramycin A offers translational researchers a mechanistically distinctive way to interrogate G-C-rich DNA binding, transcriptional control, c-myc biology, and differentiation. This article connects its established cancer research utility with a carefully bounded strategy for studying the miR-24-3p/Sp1/PI3K axis in doxorubicin-related cardiac models.

• 10074-G5: A Translational Lens on c-Myc Biology

  2026-08-20

  A mechanistic and strategic guide to using 10074-G5 as a c-Myc inhibitor, connecting c-Myc/TERT/NFκB signaling with cancer research, apoptosis assays, cell cycle arrest, and tumor regression studies.

• 10074-G5: Practical c-Myc Inhibitor Workflows

  2026-08-19

  Build a disciplined 10074-G5 workflow for connecting c-Myc/Max disruption with viability, apoptosis, cell cycle, and pathway assays. This guide translates findings from esophageal adenocarcinoma research into practical dose selection, controls, troubleshooting, and translational cancer research strategies.

• AICAR and AMPK: From Energy to Inflammation

  2026-08-19

  A translational perspective on how AICAR, a cell-permeable AMPK activator, can connect energy metabolism regulation with macrophage-driven inflammation, obesity-related asthma, experimental rigor, and preclinical strategy.

• Bleomycin Sulfate: Applied Fibrosis Workflows

  2026-08-18

  Build reproducible DNA-damage and pulmonary fibrosis models with Bleomycin Sulfate, from concentration-finding in cultured cells to pathway-resolved animal studies. This guide connects practical assay design with mitochondrial IRF3, mitophagy, ferroptosis, and TGF-β-driven fibrosis biology.

• Mithramycin A: Sp1 Assay Workflows & Troubleshooting

  2026-08-17

  Mithramycin A provides a practical transcription-perturbation tool for testing G-C-rich regulatory programs, including c-myc and Sp1-linked responses. This workflow-focused guide covers stock preparation, dose and time-course design, cardiac-model translation, assay controls, and troubleshooting for cancer biology research.

• Mithramycin A: From DNA Binding to Assay Design

  2026-08-17

  Mithramycin A is an anticancer antibiotic that converts G-C-rich DNA recognition into a powerful experimental probe of transcription. This article explains how to interpret its effects alongside the miR-24-3p/Sp1/PI3K findings and design more discriminating cancer biology research assays.

• PPACK Dihydrochloride: Thrombin Research Guide

  2026-08-16

  PPACK Dihydrochloride is an irreversible thrombin inhibitor for mechanistic coagulation and platelet studies. Its reported Ki of 0.24 nM for human α-thrombin supports use in thrombin inhibition assay design, while separate NF449 evidence should not be mistaken for PPACK evidence.

• OCT2/MATE1 Inhibition by 5-HT3 Antagonists

  2026-08-15

  George and colleagues used complementary transporter-expressing cell models to compare how five 5-HT3 antagonists affect renal OCT2- and MATE1-mediated cation transport. The results identify compound- and transporter-dependent inhibition, supporting closer evaluation of renal secretion and potential drug–drug interactions involving cationic medicines.

• WM-8014 for Reproducible Cell Assays

  2026-08-14

  Learn how WM-8014 (SKU A8779) can help distinguish cytostatic responses from general cytotoxicity in viability, proliferation, and senescence experiments. This scenario-driven guide covers mechanism, assay design, formulation constraints, interpretation, and practical product-selection criteria.

• MEK/ERK, c-Myc, and TERT in Human Stem Cells

  2026-08-14

  This bioRxiv study identifies a regulatory circuit in which MEK1/2–ERK signaling and c-Myc:MAX cooperate to keep the TERT promoter active in human embryonic stem cells. Its central mechanistic insight is that loss of either kinase signaling or c-Myc:MAX activity permits polycomb-associated H3K27me3 accumulation, providing a chromatin-level explanation for reduced TERT transcription.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-08-13

  Dimethyloxalylglycine (DMOG) is a cell-permeable PHD inhibitor used to stabilize HIF-1α and model hypoxia-related signaling under controlled experimental conditions. It is appropriate for research on oxygen sensing, hypoxia responses, and inflammation, but it is not intended for diagnostic, therapeutic, or medical use.

• Panobinostat (LBH589): Mechanism and Research Workflow

  2026-08-13

  Panobinostat, also called LBH589, is a hydroxamic acid-based broad-spectrum HDAC inhibitor used to study histone acetylation, apoptosis, and cancer-cell drug resistance. Product information reports low-nanomolar activity in selected leukemia-cell assays and tumor-growth inhibition in an intraperitoneal xenograft model, but assay conditions and model details must be checked before quantitative comparison.

• Pseudo-UTP for mRNA Synthesis Workflows

  2026-08-12

  Pseudo-UTP enables controlled pseudouridine substitution during in vitro transcription, supporting RNA stability enhancement, translation studies, and immune-response investigations. This practical guide covers reaction setup, analytical confirmation, application-specific benchmarking, and troubleshooting for reproducible modified RNA production.

3776 records 8/252 page Previous Next First page 上5页 678910 下5页 Last page